DCAF7 and hepatocellular carcinoma: CCK-8 assay disclosed that DCAF7-knockdown sensitized HCC cells to sorafenib significantly (Fig. 7A, B), supporting that DCAF7 is a critical determinant of sorafenib efficacy.